Novo Holdings
Novo Holdings
Revolutionizing Antibody Production: Speed Up Your Solutions!
Unlock the future of healthcare! 🚀 Discover how NGS workflows accelerate antibody development and streamline manufacturing for better patient outcomes. 🔬⚗️📈
Cancer ADC Specialist Myricx Bio Secures £90m in Funding Expanding Pipeline and Board
📢 Novo Holdings AS and Abingworth co-lead £90m financing in Myricx Bio Ltd, with plans to expand their ADC platform. 💰
Gene Therapy Breakthrough Acquisition and Bankruptcy Shake Biotech Industry!
📰 Intellia and Ultragenyx's clinical updates, Novo Holdings' Catalent acquisition, and NanoString bankruptcy; Simon Barnett 💊💼💥💡
Game-Changing Novo Catalent Deal Revolutionizes CGT Outsourcing
📢 Get ready for a game-changer! The Novo Catalent deal is about to shake up the CGT outsourcing space. 💥🧪💼
Novo Holdings Acquires Catalent for $165B Sells Sites for $11B: Tapping into Obesity and Diabetes Drug Market
📢 Novo Holdings acquires Catalent for $16.5B 💰 and sells 3 sites to Novo Nordisk for $11B 💼 to meet demand for obesity and diabetes drugs.
Novo Holdings Acquires Catalent for $165bn: Expanding Presence in Pharma Manufacturing
📢 Novo Holdings acquires CDMO Catalent for $16.5bn, expanding their presence in pharmaceutical manufacturing and development. 💼💉🌍
Novo Holdings Invests $165bn in CDMO Catalent Fueling Biotech Growth
🔍 Novo Holdings buys CDMO Catalent for $16.5bn, aiming to support its expansion in the CDMO market. 🏢💼📈
